Results 11 to 20 of about 101,340 (329)

Dopamine Agonists and Pathologic Behaviors [PDF]

open access: yesParkinson's Disease, 2012
The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as ...
Brendan J. Kelley   +2 more
doaj   +3 more sources

From Selye’s and Szabo’s Cysteamine-Duodenal Ulcer in Rats to Dopamine in the Stomach: Therapy Significance and Possibilities

open access: yesPharmaceuticals, 2023
We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric   +24 more
doaj   +1 more source

Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]

open access: yesPLoS ONE, 2014
BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko   +4 more
doaj   +1 more source

Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it

open access: yesAlʹmanah Kliničeskoj Mediciny, 2023
The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj   +1 more source

Dopamine agonists and antipsychotics [PDF]

open access: yesEuropean Journal of Endocrinology, 2020
There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire   +2 more sources

Cholinergic modulation of dopamine overflow in the rat neostriatum: A fast cyclic voltammetric study in vitro [PDF]

open access: yes, 1994
Stimulus-evoked dopamine overflow in rat neostriatal slices was determined using fast cyclic voltammetry. The dopamine efflux induced by intrastriatal stimulation increased with stimulus intensity and was found to be enhanced by more than 100% upon ...
Kudernatsch, Martina, Sutor, Bernd
core   +1 more source

Could dopamine agonists aid in drug development for anorexia nervosa? [PDF]

open access: yes, 2014
Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage-years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight, and an often delusional quality ...
Frank, Guido KW
core   +2 more sources

Predictors of dopamine agonist resistance in prolactinoma patients

open access: yesBMC Endocrine Disorders, 2020
Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen   +6 more
doaj   +1 more source

Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]

open access: yes, 2014
In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core   +1 more source

Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment [PDF]

open access: yes, 1997
Neuropsychiatric side effects often complicate anti-Parkinsonian therapy and pose a significant problem in the optimal management of idiopathic Parkinson's disease.
Abbott, R.J.   +6 more
core   +2 more sources

Home - About - Disclaimer - Privacy